Drug Trial Radar · NCT05245604
Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients
Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
182
Planned (sponsor's estimate)
Start
Jun 19, 2020
Primary completion
Aug 2022
Study completion Apr 2023
Sponsor
- Lead sponsor
- Taejoon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.
Conditions
- Dry Eye Syndrome
Interventions
TJO-087Drug
Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
Cyclosporine ophthalmic solution 0.05%Drug
Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Non-anesthetic Schirmer Test at Week 32Time frame: Baseline and Week 32
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hyo Myung, Kim
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.